

## Florence

Auditorium al Duomo ITALY



## **Background**

Aerosol medications are replacing orally administered drugs that are used in the treatment of respiratory diseases and may come to play a major future role in the treatment of other diseases that require delivery of drugs into the systemic circulation. There are many advantages to aerosolized drug delivery to the lungs. This route of administration is noninvasive, provides a faster onset of action for short-acting bronchodilators, compared to oral therapy, allows for lower doses of antibiotics and corticosteroids for the same effect as oral or injection therapy, avoids side-effects associated with oral and injection therapy and avoids the pain associated with injection therapy.

Many therapeutic drugs are currently being administered to the lung by aerosol and many new devices are now available for delivering

aerosolised medications. However, there are also many challenges to optimizing delivery of aerosolized drugs by the pulmonary route. To meet these challenges, we need to: 1, be aware of the effect of particle size and density on pulmonary aerosol deposition; 2, understand the need for specific inhalation manoeuvres to ensure delivery with available devices; 3, be aware that the effect of lung disease on aerosol deposition means that medication may not penetrate to smaller airways when the patient is severely obstructed; 4, the effect of lung disease on aerosol deposition means that patients with severe obstruction may not be good candidates for aerosol therapies that require uniform deposition patterns, or deposition in the deep lung; 5, to select the proper aerosol delivery device.

#### Aim of the meeting

The aim of the meeting is to present most recent aerosol research findings to an intellectually engaged, diverse and professionally-dedicated community and immerse attendances into the latest advances across the spectrum of aerosol research. The hope is to boost a vivid discussion and novel proposal that may create and added value for academic and industrial research and provide new hope to patients.

### **Educational aims**

- y understand basic aerosol science
- understand key issues of treating diseased airways
- understand patient related factors influencing efficacy of aerosol therapy
- y understand key factors to instruct and monitor technical skills of patients
- understand key factors related to regulatory issues
- y understand specific pharmacokinetic/dynamic issues related to aerosol medicine

October 18th - 19th, 2019
Florence
Auditorium al Duomo
ITALY

## **FACULTY**

#### **Scientific Committee**

Prof. Federico Lavorini, Italy

Peter John Barnes. UK Ruggero Bettini, Italy Martin Biddiscombe, UK Francesco Blasi, Italy Francesca Buttini, Italy Henry Chrystyn, UK Lorenzo Corbetta, Italy Chris Corrigan, UK Angelo Guido Corsico, Italy Borja Garcia Cosio, Espana Richard Costello, Ireland Roberto Dal Negro, Italy Richard Dekhuijzen, NI Rajiv Dhand, USA Giovanni Fontana, Italy Riccardo Guarise, Italy Paul Hagedoorn, NI Federico Lavorini, Italy Mark Levy, UK Darragh Murnane, UK Alberto Papi, Italy Soren Pedersen, Denmark Massimo Pistolesi, Italy John Nigel Pritchard, UK Nicolas Roche, France Paola Rogliani, Italy John Scullion, UK Omar Usmani, UK Job van der Palen, NI





IN INHALATION THERAPY

14.00-14.30

Participants registration

14.30-14.45

Opening of the meeting - F. Lavorini (I)

14.45-16.00

**SESSION 1 BASIC AEROSOL SCIENCE** 

Chairmen:

R. Bettini (I).

G. Fontana (I)

Definition and description of an aerosol

D. Murnane (UK)

15.05-15.25

In vitro testing of pharmaceutical aerosols

F. Buttini (I)

15.25-15.45

Imaging techniques for assessing aerosol deposition

M. Biddiscombe (UK)

15.45-16.00

Targeting the lungs with therapeutic aerosol

O. Usmani (UK)

16.00-16.30 **BREAK** 

16.30-17.45

**SESSION 2** 

**GENERATION OF THERAPEUTIC AEROSOLS** 

Pressurised metered dose inhalers

Chairmen:

16.30-16.50

and spacers

16.50-17.10

17.10-17.30

C. Corrigan (UK)

Dry powder inhalers

P. Hagedoorn (NL)

L. Corbetta (I).

R. Dal Negro (I)

IN COPD Chairman:

17.45-19.20

**SESSION 3** 

**NEW TRENDS** 

P.J. Barnes (UK).

F. Blasi (I)

14.45-15.05

17.30-17.45

Criteria to select an aerosol generator

Nebulisers and soft mist inhalers

R. Dekhuijzen (NL)

J.N. Pritchard (UK)

17.45-18.15

Triple therapy in COPD

A. Papi (I)

18.15-18.45

Dual bronchodilator therapy in COPD

P. Rogliani (I)

18.45-19.00

Triple or dual? This is the question!

The final verdict

P.J. Barnes (UK)

19.00-19.20

Final discussion on topics above mentioned



OF INHALATION THERAPY

09.00-10.15

SESSION 4
AEROSOLS
TO TREAT
RESPIRATORY
DISEASES

Chairmen:

F. Lavorini (I), S. Pedersen (S)

09.00-09.20

Aerosol therapy in asthma

M. Levy (UK)

09.20-09.40

Aerosol therapy in COPD and non CF bronchiectasis

B.G. Cosio (E)

09.40-10.00

Delivery of therapeutic aerosols during mechanical ventilation

R. Dhand (US)

10.00-10.15

Aerosol therapy in cystic fibrosis

R. Guarise (I)

10.15-10.45 BREAK 10.45-13.30

SESSION 5

EDUCATING PATIENTS
IN CORRECT USE OF
AEROSOL GENERATORS

Chairmen:

R. Dekhuijzen (NL), M. Pistolesi (I)

10.45-11.05

Traying but failing:

The role of inhaler technique in respiratory medication adherence

H. Chrystyn (UK)

11.05-11.25

Evaluating and teaching use of inhalers in patients with asthma or COPD

J. Scullion (UK)

11.25-11.45

Exacerbation and inhaler technique errors

N. Roche (F)

11.45-12.00

Electronic medication monitors to assess and promote adherence to asthma medications

R. Costello (IR)

12.00-12.30

**LECTURE (NON CME)** 

Improving adherence by using a once-daily, single-inhaler combination therapy"

Speaker: J. van der Palen (NL)

12.30-13.00

**LECTURE** 

Breath-Actuated MDI: The Third Way"

Chairman: F. Lavorini (I) Speaker: A. Corsico (I)

13.00-13.30

Final discussion on topics above mentioned and concluding remarks

F. Lavorini (I)

13.30-13.45

CME Quiz

# GENERAL INFORMATION

Congress Venue Congress Centre Auditorium al Duomo Via de 'Cerretani 54/R 50123 Florence (Italy)



A fixed maximum number of 100 participants will be admitted to the Congress. The official language is English. No simultaneous translation will provided.

#### The Registration includes:

- Admission to full scientific program
- Congress Kit
- Certificate of Attendance
- Coffee Breaks and Lunches

#### **CME - Continuing Medical Education Accreditation**

We are pleased to inform you that the Congress (ID CME 275-270150) has been granted 8 CME credits.

The congress is addressed to Medical Doctors specialized in:

- · Allergy and clinical immunology
- Geriatrics
- General Medicine
- Internal Medicine
- Paediatrics
- · Physiology and in diseases of the respiratory

Provider (ID 275) & Congress Secretariat



Via San Gregorio, 12 20124 MILANO (Italy) Tel. +39 02 49453331 Fax +39 02 87036090 info@infomed-online.it

www.infomed-online.it